Mineralys Therapeutics, Inc. Common Stock
Symbol: MLYS (NASDAQ)
37.35
▼ (-6.32%) -2.520
Company Description:
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Key Stats
- Today's Open: $39.53
- Today's High: $41.339
- Today's Low: $37.35
- Today's Volume: 2.48M
- Yesterday Close: $39.87
- Yesterday High: $40.33
- Yesterday Low: $36.77
- Yesterday Volume: 1.53M
- Last Min Volume: 5
- Last Min High: $37.35
- Last Min Low: $37.35
- Last Min VWAP: $37.35
Company Profile
- Name: Mineralys Therapeutics, Inc. Common Stock
- Website: https://mineralystx.com
- Listed Date: 2023-02-10
- Location: RADNOR, PA
- Market Status: Active
- CIK Number: 0001933414
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $3.05B
- Round Lot: 100
- Outstanding Shares: 77.57M
- Asset Type: CS
RECENT FILINGS FOR MLYS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-16 | 4 | View |
| 2025-09-15 | 144 | View |
| 2025-09-08 | 4 | View |
| 2025-09-08 | SCHEDULE 13D/A | View |
| 2025-09-08 | SCHEDULE 13D/A | View |
| 2025-09-08 | 4 | View |
| 2025-09-03 | 8-K | View |
| 2025-09-03 | 424B5 | View |
| 2025-09-02 | S-3MEF | View |
| 2025-09-02 | 8-K | View |
| 2025-09-02 | 424B5 | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | 144 | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-07-30 | 4 | View |
| 2025-07-30 | 144 | View |
| 2025-07-30 | 144 | View |
Latest News on MLYS